227 related articles for article (PubMed ID: 30543698)
1. A unique subset of low-risk Wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A Children's Oncology Group study.
Armstrong AE; Gadd S; Huff V; Gerhard DS; Dome JS; Perlman EJ
PLoS One; 2018; 13(12):e0208936. PubMed ID: 30543698
[TBL] [Abstract][Full Text] [Related]
2. TRIM28 haploinsufficiency predisposes to Wilms tumor.
Diets IJ; Hoyer J; Ekici AB; Popp B; Hoogerbrugge N; van Reijmersdal SV; Bhaskaran R; Hadjihannas M; Vasileiou G; Thiel CT; Seven D; Uebe S; Ilencikova D; Waanders E; Mavinkurve-Groothuis AMC; Roeleveld N; de Krijger RR; Wegert J; Graf N; Vokuhl C; Agaimy A; Gessler M; Reis A; Kuiper RP; Jongmans MCJ; Metzler M
Int J Cancer; 2019 Aug; 145(4):941-951. PubMed ID: 30694527
[TBL] [Abstract][Full Text] [Related]
3. Germline mutations and somatic inactivation of TRIM28 in Wilms tumour.
Halliday BJ; Fukuzawa R; Markie DM; Grundy RG; Ludgate JL; Black MA; Skeen JE; Weeks RJ; Catchpoole DR; Roberts AGK; Reeve AE; Morison IM
PLoS Genet; 2018 Jun; 14(6):e1007399. PubMed ID: 29912901
[TBL] [Abstract][Full Text] [Related]
4. TRIM28 variants and Wilms' tumour predisposition.
Hol JA; Diets IJ; de Krijger RR; van den Heuvel-Eibrink MM; Jongmans MC; Kuiper RP
J Pathol; 2021 Jul; 254(4):494-504. PubMed ID: 33565090
[TBL] [Abstract][Full Text] [Related]
5. TRIM28 inactivation in epithelial nephroblastoma is frequent and often associated with predisposing TRIM28 germline variants.
Wegert J; Fischer AK; Palhazi B; Treger TD; Hilgers C; Ziegler B; Jung H; Jüttner E; Waha A; Fuchs J; Warmann SW; Frühwald MC; Hubertus J; Pritchard-Jones K; Graf N; Behjati S; Furtwängler R; Gessler M; Vokuhl C
J Pathol; 2024 Jan; 262(1):10-21. PubMed ID: 37792584
[TBL] [Abstract][Full Text] [Related]
6. Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.
Ooms AH; Gadd S; Gerhard DS; Smith MA; Guidry Auvil JM; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Ma Y; Zong Z; Mungall AJ; Moore RA; Marra MA; Huff V; Dome JS; Chi YY; Tian J; Geller JI; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Walz AL; van den Heuvel-Eibrink MM; de Krijger RR; Ross N; Gastier-Foster JM; Perlman EJ
Clin Cancer Res; 2016 Nov; 22(22):5582-5591. PubMed ID: 27702824
[TBL] [Abstract][Full Text] [Related]
7.
Moore C; Monforte H; Teer JK; Zhang Y; Yoder S; Brohl AS; Reed DR
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32699065
[TBL] [Abstract][Full Text] [Related]
8. Wilms tumour resulting from paternal transmission of a TRIM28 pathogenic variant-A first report.
Whitworth J; Armstrong R; Maher ER
Eur J Hum Genet; 2024 Mar; 32(3):361-364. PubMed ID: 38282073
[TBL] [Abstract][Full Text] [Related]
9. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.
Gadd S; Huff V; Huang CC; Ruteshouser EC; Dome JS; Grundy PE; Breslow N; Jennings L; Green DM; Beckwith JB; Perlman EJ
Neoplasia; 2012 Aug; 14(8):742-56. PubMed ID: 22952427
[TBL] [Abstract][Full Text] [Related]
10. The WTX Tumor Suppressor Interacts with the Transcriptional Corepressor TRIM28.
Kim WJ; Wittner BS; Amzallag A; Brannigan BW; Ting DT; Ramaswamy S; Maheswaran S; Haber DA
J Biol Chem; 2015 Jun; 290(23):14381-90. PubMed ID: 25882849
[TBL] [Abstract][Full Text] [Related]
11. Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the Children's Oncology Group AREN18B5-Q.
Murphy AJ; Cheng C; Williams J; Shaw TI; Pinto EM; Dieseldorff-Jones K; Brzezinski J; Renfro LA; Tornwall B; Huff V; Hong AL; Mullen EA; Crompton B; Dome JS; Fernandez CV; Geller JI; Ehrlich PF; Mulder H; Oak N; Maciezsek J; Jablonowski CM; Fleming AM; Pichavaram P; Morton CL; Easton J; Nichols KE; Clay MR; Santiago T; Zhang J; Yang J; Zambetti GP; Wang Z; Davidoff AM; Chen X
Nat Commun; 2023 Dec; 14(1):8006. PubMed ID: 38110397
[TBL] [Abstract][Full Text] [Related]
12. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.
Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506
[TBL] [Abstract][Full Text] [Related]
13. Identification of new Wilms tumour predisposition genes: an exome sequencing study.
Mahamdallie S; Yost S; Poyastro-Pearson E; Holt E; Zachariou A; Seal S; Elliott A; Clarke M; Warren-Perry M; Hanks S; Anderson J; Bomken S; Cole T; Farah R; Furtwaengler R; Glaser A; Grundy R; Hayden J; Lowis S; Millot F; Nicholson J; Ronghe M; Skeen J; Williams D; Yeomanson D; Ruark E; Rahman N
Lancet Child Adolesc Health; 2019 May; 3(5):322-331. PubMed ID: 30885698
[TBL] [Abstract][Full Text] [Related]
14. A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor.
Gadd S; Huff V; Walz AL; Ooms AHAG; Armstrong AE; Gerhard DS; Smith MA; Auvil JMG; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Hermida LC; Davidsen T; Gesuwan P; Ma Y; Zong Z; Mungall AJ; Moore RA; Marra MA; Dome JS; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Ross N; Gastier-Foster JM; Arold ST; Perlman EJ
Nat Genet; 2017 Oct; 49(10):1487-1494. PubMed ID: 28825729
[TBL] [Abstract][Full Text] [Related]
15. Anaplasia and drug selection-independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor.
Re GG; Willingham MC; el Bahtimi R; Brownlee NA; Hazen-Martin DJ; Garvin AJ
Mod Pathol; 1997 Feb; 10(2):129-36. PubMed ID: 9127318
[TBL] [Abstract][Full Text] [Related]
16. Wilms tumor: an update.
Al-Hussain T; Ali A; Akhtar M
Adv Anat Pathol; 2014 May; 21(3):166-73. PubMed ID: 24713986
[TBL] [Abstract][Full Text] [Related]
17. A Gradual Transition Toward Anaplasia in Wilms Tumor Through Tolerance to Genetic Damage.
Uno K; Rastegar B; Jansson C; Durand G; Valind A; Chattopadhyay S; Bertolotti A; Ciceri S; Spreafico F; Collini P; Perotti D; Mengelbier LH; Gisselsson D
Mod Pathol; 2024 Jan; 37(1):100382. PubMed ID: 37951357
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.
Maschietto M; Williams RD; Chagtai T; Popov SD; Sebire NJ; Vujanic G; Perlman E; Anderson JR; Grundy P; Dome JS; Pritchard-Jones K
PLoS One; 2014; 9(10):e109924. PubMed ID: 25313908
[TBL] [Abstract][Full Text] [Related]
19. TRIM28-Regulated Transposon Repression Is Required for Human Germline Competency and Not Primed or Naive Human Pluripotency.
Tao Y; Yen MR; Chitiashvili T; Nakano H; Kim R; Hosohama L; Tan YC; Nakano A; Chen PY; Clark AT
Stem Cell Reports; 2018 Jan; 10(1):243-256. PubMed ID: 29290627
[TBL] [Abstract][Full Text] [Related]
20. The complexity of TRIM28 contribution to cancer.
Czerwińska P; Mazurek S; Wiznerowicz M
J Biomed Sci; 2017 Aug; 24(1):63. PubMed ID: 28851455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
